Skip to main content
Premium Trial:

Request an Annual Quote

Losses and Lack of Cash at Sequenom Causes Its Accounting Firm to Identify Going Concern in 2005 Results

NEW YORK, April 7 (GenomeWeb News) - Sequenom's accounting firm has issued a "going concern qualification" on the company's financial statements for the year 2005, the company said yesterday.


Ernst & Young, Sequenom's independent registered public accounting firm, issued the concern on the 2005 results, filed on March 31, because of the company's significant operating losses and insufficient cash and investments to fund operations past the second quarter of 2006.


Last week, the company announced a private stock placement of $30 million, which it increased to $33 million on Monday.


As of Dec. 31, 2005, the company had $8.7 million in cash, cash equivalents, short-term investments and restricted cash. Net losses for 2005 declined to $26 million from $34 million year over year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more